ArticleAnalytical and bioanalytical chemistry2026
Development of a hypersensitive digital ELISA system for hepatitis B core antigen.
Article in Analytical and bioanalytical chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Chronic hepatitis B (CHB) is a global health threat caused by the hepatitis B virus (HBV). Nucleos(t)ide analogs (NUCs) are the standard treatment for CHB patients with HBV replication. However, NUCs cannot eliminate covalently closed circular DNA (cccDNA), the template for HBV replication, from the nuclei of hepatocytes; hence, patients with CHB need life-long treatment with NUCs because HBV relapses easily upon cessation of NUCs because of the residual cccDNA. However, NUCs can be terminated by accurately monitoring the activity of the cccDNA. Despite the recent development of highly sensitive detection systems for HBV biomarkers, the detection accuracy remains poor, especially at lower concentrations. Therefore, it is desirable to develop more sensitive and reliable biomarkers that have a good correlation with cccDNA, even at lower concentrations. In this study, we developed a digital enzyme-linked immunosorbent assay (ELISA) system for detecting hepatitis B core antigen (HBcAg) using a pair of monoclonal antibodies. The digital ELISA system successfully detected 2.9 pg/mL, which can be converted to 58 aM HBcAg, and the sensitivity was approximately 1000 times higher than that of conventional ELISA. Furthermore, the influence of plasma and serum matrices on the sensitivity can be ignored if the concentrations of the matrices are 1% or less. In addition, the antibody-blocking assay indicated that the digital ELISA system reacted specifically with HBcAg, even in the presence of serum or plasma. Collectively, our highly sensitive digital ELISA system for detecting HBcAg is a potentially new approach for evaluating therapeutic strategies for CHB.
Indexed as
Identifiers
41572036What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.